PEA (Palmitoylethanolamide)

Good evidence for chronic pain and neuroinflammation; well-tolerated with a favorable safety profile.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Multiple RCTs support PEA for neuropathic pain, sciatica, and chronic inflammatory pain. Meta-analyses show significant pain reduction versus placebo.

• Reduces chronic and neuropathic pain
• Anti-inflammatory via mast cell stabilization
• May support neuroprotection
• No known drug interactions

600–1200 mg daily in divided doses. Micronized (PEA-m) or ultra-micronized (PEA-um) forms preferred.

• Mild GI discomfort (rare)
• Generally very well tolerated

Generally well-tolerated. Limited long-term safety data beyond 3 months in trials.

Micronized and ultra-micronized forms have better bioavailability than standard PEA powder.

• Pain72
• Recovery50
• Mood35